Innovent Biologic has received approval by the National Medical Products Administration, NMPA, in China for a new indication for the treatment of adult patients with chronic lymphocytic leukemia or small lymphocytic lymphoma, CLL/SLL, after at least one line of systemic therapy including a Bruton’s tyrosine kinase inhibitor.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IVBXF:
- Innovent Wins China Approval for New Jaypirca Leukemia Indication
- Why Did Innovent Biologics Shares Surge?
- Innovent Biologics announces collaboration with Lilly
- Innovent Strikes US$8.85 Billion Global Oncology and Immunology Pact With Eli Lilly
- Innovent Surpasses RMB10 Billion in 2025 Product Revenue on Oncology and Chronic Disease Momentum